Search results for "recombinant protein"

showing 10 items of 707 documents

Granulocyte-macrophage colony-stimulating factor induces cytokine secretion by human polymorphonuclear leukocytes.

1989

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is known as an inducer of proliferation and functional activation of myeloid cells. This study was carried out to characterize the effects of GM-CSF on polymorphonuclear leukocytes (PMN) more extensively. Using Northern blot analysis, we show that PMN are able to accumulate mRNAs for different cytokines, including tumor necrosis factor-alpha (TNF-alpha); G-CSF, and M-CSF, all of which are involved in inflammation and hematopoiesis. Biological assays and immunoassays demonstrate that PMN translate these mRNAs, except TNF-alpha, into secretory proteins. However, the expression of these cytokines is dependent on stimulation by exogenous…

Macrophage colony-stimulating factorNeutrophilsT cellInflammationBiologyBiological FactorsMiceColony-Stimulating FactorsGranulocyte Colony-Stimulating FactormedicineAnimalsHumansRNA MessengerGrowth SubstancesTumor Necrosis Factor-alphaMacrophage Colony-Stimulating FactorLymphokineGranulocyte-Macrophage Colony-Stimulating FactorGeneral MedicineColony-stimulating factorRecombinant ProteinsRetractionCell biologymedicine.anatomical_structureGranulocyte macrophage colony-stimulating factorImmunologyCytokinesTumor necrosis factor alphaCytokine secretionmedicine.symptomResearch Articlemedicine.drugJournal of Clinical Investigation
researchProduct

Transient structural ordering of the RNA-binding domain of carnation mottle virus p7 movement protein modulates nucleic acid binding.

2005

Plant viral movement proteins bind to RNA and participate in the intra- and intercellular movement of the RNAs from plant viruses. However, the role and magnitude of the conformational changes associated with the formation of RNA-protein complexes are not yet defined. Here we describe studies on the relevance of a preexisting nascent alpha-helix at the C terminus of the RNA-binding domain of p7, a movement protein from carnation mottle virus, to RNA binding. Synthetic peptide analogues and single amino acid mutation at the RNA-binding domain of recombinant p7 protein were used to correlate the transient structural order in aqueous solution with RNA-binding potential.

Magnetic Resonance SpectroscopyMolecular Sequence DataBiochemistryViral ProteinsPlant virusAmino Acid SequenceBinding siteMovement proteinMolecular BiologyBinding SitesbiologyC-terminusOrganic ChemistryRNARNA-Binding Proteinsbiology.organism_classificationRecombinant ProteinsProtein Structure TertiarySpectrometry FluorescenceBiochemistryCarnation mottle virusMutationNucleic acidMolecular MedicineRNAPeptidesBinding domainChembiochem : a European journal of chemical biology
researchProduct

IL-33/ST2 pathway regulates neutrophil migration and predicts outcome in patients with severe alcoholic hepatitis.

2020

Background & Aims Severe alcoholic hepatitis (SAH) is associated with a high risk of infection. The IL-33/ST2 pathway is involved in sepsis control but data regarding its role in alcohol-related liver disease (ALD) are lacking. We aimed to characterize the role of IL-33/ST2 in the polymorphonuclear neutrophils (PMNs) of patients with ALD and SAH. Methods Serum and circulating neutrophils were collected from patients with SAH, alcoholic cirrhosis and healthy controls. We quantified IL-33/ST2 pathway activity and CXCR2 at baseline and after exposure to IL-33. We also determined the migration capacity of PMNs. Results The decoy receptor of IL-33 (soluble ST2 [sST2]) was increased in SAH vs. ci…

Male0301 basic medicineAlcoholic liver diseaseCirrhosisPolymorphonuclear neutrophilsNeutrophils[SDV.MHEP.PHY] Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]ApoptosisGastroenterologyReceptors Interleukin-8BLiver disease0302 clinical medicineCell MovementLiver Cirrhosis AlcoholicProspective StudiesCXC chemokine receptorsReceptorCells CulturedMigrationMiddle AgedPrognosisRecombinant Proteins3. Good healthCirrhosisAlcoholic hepatitis;Cirrhosis;Infection;Interleukin-33;Migration;Polymorphonuclear neutrophilsFemale030211 gastroenterology & hepatologyAlcoholic hepatitisInfectionSignal TransductionAdultmedicine.medical_specialtyAlcoholic hepatitisSepsis03 medical and health sciencesInternal medicinemedicine[SDV.MHEP.PHY]Life Sciences [q-bio]/Human health and pathology/Tissues and Organs [q-bio.TO]Humanscardiovascular diseasesAgedHepatologyHepatitis Alcoholicbusiness.industrymedicine.diseaseInterleukin-33Interleukin-1 Receptor-Like 1 Proteinnervous system diseasesInterleukin 33030104 developmental biologyCase-Control StudiesbusinessFollow-Up Studies
researchProduct

Single intracerebroventricular progranulin injection adversely affects the blood–brain barrier in experimental traumatic brain injury

2021

Progranulin (PGRN) is a neurotrophic and anti-inflammatory factor with protective effects in animal models of ischemic stroke, subarachnoid hemorrhage, and traumatic brain injury (TBI). Administration of recombinant (r) PGRN prevents exaggerated brain pathology after TBI in Grn-deficient mice, suggesting that local injection of recombinant progranulin (rPGRN) provides therapeutic benefit in the acute phase of TBI. To test this hypothesis, we subjected adult male C57Bl/6N mice to the controlled cortical impact model of TBI, administered a single dose of rPGRN intracerebroventricularly (ICV) shortly before the injury, and examined behavioral and biological effects up to 5 days post injury (dp…

Male0301 basic medicinemedicine.medical_specialtySubarachnoid hemorrhageTraumatic brain injuryPrimary Cell Culture610 MedizinBlood–brain barrierOccludinBiochemistryNeuroprotectionMice03 medical and health sciencesCellular and Molecular NeuroscienceProgranulins0302 clinical medicineInternal medicine610 Medical sciencesBrain Injuries TraumaticmedicineAnimalsNeuroinflammationInjections IntraventricularTight Junction ProteinsBehavior AnimalMicrogliabiologybusiness.industrymedicine.diseaseRecombinant ProteinsMice Inbred C57BL030104 developmental biologymedicine.anatomical_structureEndocrinologyAnimals NewbornBlood-Brain BarrierAstrocytesbiology.proteinEncephalitisMicrogliabusiness030217 neurology & neurosurgeryNeurotrophin
researchProduct

Enhanced Activity of Meprin-α, a Pro-Migratory and Pro-Angiogenic Protease, in Colorectal Cancer

2011

Meprin-α is a metalloprotease overexpressed in cancer cells, leading to the accumulation of this protease in a subset of colorectal tumors. The impact of increased meprin-α levels on tumor progression is not known. We investigated the effect of this protease on cell migration and angiogenesis in vitro and studied the expression of meprin-α mRNA, protein and proteolytic activity in primary tumors at progressive stages and in liver metastases of patients with colorectal cancer, as well as inhibitory activity towards meprin-α in sera of cancer patient as compared to healthy controls. We found that the hepatocyte growth factor (HGF)- induced migratory response of meprin-transfected epithelial c…

MaleAngiogenesisColorectal cancerCancer TreatmentGene Expressionlcsh:MedicineBiochemistry0302 clinical medicineCell MovementMolecular Cell BiologyGastrointestinal CancersMorphogenesisPathologylcsh:ScienceAged 80 and over0303 health sciencesMetalloproteinaseMultidisciplinaryHepatocyte Growth FactorLiver NeoplasmsMetalloendopeptidasesMiddle AgedImmunohistochemistryRecombinant ProteinsEnzymes3. Good healthOncology030220 oncology & carcinogenesisMedicineFemaleHepatocyte growth factorAntiangiogenesis TherapyColorectal NeoplasmsResearch Articlemedicine.drugAdultmedicine.medical_specialtyImmunoblottingHistopathologyNeovascularization PhysiologicCell MigrationGastroenterology and HepatologyIn Vitro TechniquesBiologyMannose-Binding LectinCell LineRectal CancerYoung Adult03 medical and health sciencesDogsDiagnostic MedicineInternal medicineGastrointestinal TumorsmedicineAnimalsHumansImmunoprecipitationBiologyAged030304 developmental biologylcsh:RCancers and NeoplasmsCancerPlasminogenBlotting Northernmedicine.diseaseRatsEndocrinologyAnatomical PathologyTumor progressionZymogen activationCancer cellCancer researchlcsh:QDevelopmental BiologyPLoS ONE
researchProduct

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis.

1989

Recombinant human alpha-interferon is now under intensive investigation as therapy for chronic Type B hepatitis. Recent reports have suggested that prolonged alpha-interferon therapy may induce autoimmune reactions. We have evaluated the problem of autoimmunity related to alpha-interferon therapy by testing for 15 different antibodies in the sera of 31 patients treated with alpha-interferon. No patient had autoantibodies before treatment; 27 (87%) of 31 patients developed at least one autoantibody. Eleven patients had antinuclear antibodies and 21 had smooth muscle antibodies, both of which usually developed during alpha-interferon therapy. In contrast, antibodies to endocrine organs such a…

MaleAnti-nuclear antibodymedicine.medical_treatmentmedicine.disease_causeAutoimmunityAutoimmune DiseasesHepatitisPrimary biliary cirrhosisAntibody SpecificityEndocrine GlandsMedicineHumansAutoantibodiesHepatitisHepatologybiologybusiness.industryAutoantibodymedicine.diseaseHepatitis BAnti-thyroid autoantibodiesRecombinant ProteinsImmunologyChronic DiseaseInterferon Type Ibiology.proteinThyroglobulinFemaleAntibodybusinessHepatology (Baltimore, Md.)
researchProduct

5-Fluorouracil plus interferon α-2a compared to 5-fluorouracil alone in the treatment of advanced colon carcinoma: A multicentric randomized study

1998

Biochemical modulation is one of the most interesting fields in cancer chemotherapy. Interferon-alpha (IFNalpha) is a cytokine that is able to influence the pharmacodynamics of 5-fluorouracil (5FU) through a number of mechanisms. With the aim of confirming some data emerging from the literature, we initiated a multicentric randomized study comparing the combination of 5FU and IFNalpha-2a with 5FU alone in the treatment of advanced or metastatic colon cancer. A group of 205 colon cancer patients (104 in the 5FU arm and 101 in the 5FU + IFNapha-2a arm) were included in the final intention-to-treat analysis. Rectal cancers were not considered eligible. All patients had measurable disease, were…

MaleAntimetabolites AntineoplasticCancer Researchmedicine.medical_specialtyColorectal cancerAlpha interferonInterferon alpha-2GastroenterologyMetastasisInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansInterferon alfaAgedLeukopeniabusiness.industryStandard treatmentInterferon-alphaGeneral MedicineMiddle Agedmedicine.diseaseRecombinant ProteinsSurgeryOncologyFluorouracilColonic NeoplasmsFemaleFluorouracilmedicine.symptombusinessmedicine.drugJournal of Cancer Research and Clinical Oncology
researchProduct

Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia.

1998

The radiosensitivity of solid tumours in anaemic rats treated with recombinant human erythropoietin (rhEPO, epoetin beta) was studied. Anaemia was induced by a single dose of carboplatin (45 mg kg(-1) i.v.), resulting in a reduction in the haemoglobin concentration by 30%. In a second group, the development of anaemia was prevented by rhEPO (1000 IU kg(-1)) administered s.c. three times per week starting 6 days before the carboplatin application. Three days after carboplatin treatment, DS-sarcomas were implanted subcutaneously onto the hind foot dorsum. Neither carboplatin nor rhEPO treatment influenced tumour growth rate. Five days after implantation, tumours were irradiated with a single …

MaleCancer Researchmedicine.medical_specialtyAnemiamedicine.medical_treatmentUrologyAntineoplastic AgentsRadiation ToleranceCarboplatinRats Sprague-Dawleychemistry.chemical_compoundHemoglobinsInternal medicinemedicineAnimalsHumansRadiosensitivityErythropoietinEpoetin betaChemotherapybusiness.industryAnemiamedicine.diseaseCarboplatinRecombinant ProteinsRatsRadiation therapyEndocrinologyOncologychemistryErythropoietinToxicitySarcoma ExperimentalbusinessNeoplasm Transplantationmedicine.drugResearch ArticleBritish journal of cancer
researchProduct

High dose inhalation interleukin-2 therapy for lung metastases in patients with malignant melanoma.

2000

BACKGROUND The lungs are a frequent site of metastasis in patients with melanoma, and this may cause respiratory problems in the terminal phase of the illness. Inhalation interleukin (IL)-2 therapy to the lung has been piloted and appears to be well tolerated. METHODS Twenty-seven patients were treated with single agent dacarbazine and concurrent high dose inhalation IL-2 36 million IU per day). The patients previously had progressed on chemotherapy, predominately dacarbazine-based regimens. Patients included those with American Joint Committee on Cancer Stage IV melanoma, predominately those with lung metastases, but patients with extrapulmonary metastases also were allowed on the study. R…

MaleCancer Researchmedicine.medical_specialtyLung NeoplasmsDacarbazinemedicine.medical_treatmentAntineoplastic AgentsGastroenterologyMetastasisInternal medicineCause of DeathAdministration InhalationAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansAntineoplastic Agents AlkylatingMelanomaChemotherapyInhalationbusiness.industryMelanomaRespiratory diseaseRemission InductionCancerReproducibility of ResultsConfounding Factors Epidemiologicmedicine.diseaseRecombinant ProteinsSurgeryDacarbazineTreatment OutcomeOncologyConcomitantDisease ProgressionInterleukin-2FemaleSafetybusinessmedicine.drugFollow-Up StudiesCancer
researchProduct

Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients.

2012

Cetuximab is a human-murine chimeric monoclonal antibody to the epidermal growth factor receptor, active for advanced colorectal cancer treatment in combination with chemotherapy. Cetuximab mainly acts by inhibiting epidermal growth factor receptor-mediated pathways in cancer cells; however, in the human host, its IgG1 backbone may offer additional antitumor activity that includes FcγRs-mediated antibody-dependent cell cytotoxicity, phagocytosis, cross priming, and tumor-specific T-cell-mediated immune response. These mechanisms are still under active investigation. At this purpose, we have performed an immunologic investigation in advanced colon cancer patients enrolled in an ongoing phase…

MaleCancer Researchmedicine.medical_treatmentCetuximabPharmacologyDeoxycytidineAldesleukinT-Lymphocyte SubsetsImmunology and AllergyCytotoxic T cellEpidermal growth factor receptorChemoimmunotherapybiologyCetuximabAntibodies MonoclonalMiddle AgedRecombinant ProteinsAdvanced Colorectal CancerErbB ReceptorsKiller Cells NaturalFemaleFluorouracilImmunotherapyAntibodyColorectal NeoplasmsImmune-modulating Effectmedicine.drugImmunologyAntineoplastic AgentsAntibodies Monoclonal HumanizedIrinotecanDrug Administration ScheduleImmunomodulationImmune systemCell Line TumormedicineHumansPharmacologyEpidermal growth factor receptorPolychemotherapybusiness.industryImmunotherapyDendritic CellsColorectal cancerGemcitabineCase-Control StudiesCancer cellbiology.proteinInterleukin-2CamptothecinbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct